Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab
- 1 July 2013
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 156 (1) , 15-22.e1
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on afliberceptClinical Ophthalmology, 2012
- TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2009
- Is There Tachyphylaxis to Intravitreal Anti-Vascular Endothelial Growth Factor Pharmacotherapy in Age-Related Macular Degeneration?Ophthalmology, 2008
- Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2008
- Predicted biological activity of intravitreal VEGF TrapBritish Journal of Ophthalmology, 2008
- Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodiesRheumatology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameterAmerican Journal of Ophthalmology, 2004